Please login to the form below

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform.

White Papers and Resources

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

Authors: Keir LoIacono, John Rodriguez, Daniel J. O’Connor, James R. Nitzkorski, MD*, Christopher G. Twitty, PhD

Affiliations: OncoSec Medical Incorporated, San Diego, CA, and Pennington, NJ, *Division of Surgical Oncology, Vassar Brothers Medical Center, Poughkeepsie, NY

Latest Tweets

Facebook

Company Details

Oncosec

855.662.6732

Contact Website

Address:
New Jersey Headquarters
24 N. Main St
Pennington
NJ
08534
USA

Latest content on this profile

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
Authors: Keir LoIacono, John Rodriguez, Daniel J. O’Connor, James R. Nitzkorski, MD*, Christopher G. Twitty, PhDAffiliations: OncoSec Medical Incorporated, San Diego, CA, and Pennington, NJ, *Division of Surgical Oncology, Vassar Brothers Medical Center, Poughkeepsie, NY
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)